

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

VOLUNTARY ANNOUNCEMENT
UPDATE ON ACQUISITION OF 40.00% EQUITY INTEREST IN
TIANJIN TONGRENTANG

Reference is made to the voluntary announcement (the “**Announcement**”) of Livzon Pharmaceutical Group Inc.* 麗珠醫藥集團股份有限公司 (the “**Company**”, together with its subsidiaries, collectively referred to as the “**Group**”) dated 22 March 2021 in relation to the acquisition of 40.00% equity interest in Tianjin Tongrentang by the Company. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

Since the application materials required for contractual transfer of shares involved in the conditions precedent to the completion are not yet ready, on 6 April 2021, Tianjin Tasly and the Company, after amicable negotiation, entered into the Supplemental Agreement of the Share Transfer Agreement in relation to Tianjin Tongrentang Group Co., Ltd., the main contents of which are as follows:

1. Tianjin Tasly and the Company agreed that Article 3 (I) of the Agreement in relation to the timing of satisfaction of the conditions precedent to the completion shall be amended from “If all of the above conditions precedent to the completion are not satisfied by 9 April 2021 or such other date as unanimously agreed by both parties, the Agreement shall automatically be terminated and neither party shall constitute a breach of contract and shall not be liable for the breach of contract to each other.” to “If all of the above conditions precedent to the completion are not satisfied by 10 May 2021 or such other date as unanimously agreed by both parties, the Agreement shall automatically be terminated and neither party shall constitute a breach of contract and shall not be liable for the breach of contract to each other.”
2. Other terms shall be executed in accordance with the Agreement.

The Company will implement the disclosure obligations in a timely manner in accordance with the progress of the Transaction in the future. Investors are kindly reminded to pay attention to possible investment risks.

This announcement is made voluntarily by the Company.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China

6 April 2021

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Zheng Zhihua, Mr. Xie Yun, Mr. Tian Qiusheng and Mr. Wong Kam Wa.

** For identification purpose only*